Sarcoma 
Welcome,         Profile    Billing    Logout  

521 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarcoma
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/25
06/25
NCT02502786: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruiting
2
46
US
humanized anti-GD2 antibody, hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Children's Hospital Los Angeles, M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Recurrent Osteosarcoma
07/25
07/25
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG

Terminated
2
5
US
Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
04/22
10/23
Stereosarc, NCT03548428: Stereotaxic Body Irradiation of Oligometastase in Sarcoma

Recruiting
2
103
Europe
Atezolizumab, SBRT, High Dose Radiation
Centre Antoine Lacassagne, Centre Hospitalier Universitaire de Caen, Roche Pharma AG
Sarcoma, Radiosurgery
07/25
12/27
NCT05302921: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Active, not recruiting
2
5
US
Cryoablation Therapy, Cryosurgery, Cryotherapy, Cryoablation, Nivolumab, Ipilimumab
Children's National Research Institute, Bristol-Myers Squibb
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
07/25
07/25
NAVIGATE, NCT02576431 / 2015-003582-28: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Checkmark Approved for adult & pediatric patients with advanced solid tumors that harbor a NTRK gene fusion
Apr 2022 - Apr 2022: Approved for adult & pediatric patients with advanced solid tumors that harbor a NTRK gene fusion
Checkmark For locally advanced/metastatic TRK fusion thyroid cancer & metastatic lung cancer
Sep 2020 - Sep 2020: For locally advanced/metastatic TRK fusion thyroid cancer & metastatic lung cancer
Checkmark Data of patients with TRK fusion thyroid cancer [NAVIGATE]
More
Active, not recruiting
2
215
Europe, Japan, US, RoW
BAY2757556 (Larotrectinib, Vitrakvi), LOXO-101
Bayer
Solid Tumors Harboring NTRK Fusion
07/25
10/25
CABOSUN II, NCT03541902: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Checkmark Results from CABOSUN study
Oct 2018 - Oct 2018: Results from CABOSUN study
Active, not recruiting
2
32
US
Cabozantinib, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent
M.D. Anderson Cancer Center, Exelixis, National Cancer Institute (NCI)
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
07/25
07/25
SJATRT, NCT02114229: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Active, not recruiting
2
125
US
alisertib, methotrexate, MTX, cisplatin, Platinol-AQ, carboplatin, paraplatin, cyclophosphamide, cytoxan, etoposide, VP-16, Vepesid, Etoposide phosphate (Etopophos), topotecan, Hycamtin, vincristine, Oncovin, Surgical resection, surgical management, Radiation therapy, Craniospinal irradiation (CSI), Radiotherapy
St. Jude Children's Research Hospital, Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
09/25
09/27
SU2C-SARC032, NCT03092323: A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

Active, not recruiting
2
126
Europe, Canada, US, RoW
Pembrolizumab, KEYTRUDA®
Sarcoma Alliance for Research through Collaboration, Stand Up To Cancer, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma of the Extremity
09/25
09/28
MPNST, NCT04917042: Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

Recruiting
2
24
US
Tazemetostat, TAZVERIK
University of Florida, Epizyme, Inc.
Peripheral Nerve Sheath Tumor
09/25
09/25
NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Recruiting
2
30
RoW
TK216+Vincristin
Shanghai Pharmaceuticals Holding Co., Ltd
Sarcoma, Ewing
09/25
12/25
ACROPOLI, NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

Recruiting
2
184
Europe
Spartalizumab, PDR001, Tislelizumab
SOLTI Breast Cancer Research Group, Novartis
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma, Triple Negative Breast Cancer, Lung Adenocarcinoma, Cholangiocarcinoma, Cervical Carcinoma, Kidney Clear Cell Carcinoma, Stomach Adenocarcinoma, Esophageal Adenocarcinoma, Uterine Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Sarcoma, Lung Squamous Cell Carcinoma, Urothelial Carcinoma, Thyroid Carcinoma, Hepatocellular Carcinoma, Uveal Melanoma, HER2-positive Breast Cancer, Pancreatic Adenocarcinoma, Squamous Esophageal Carcinoma, Epithelial Ovarian Cancer, Uterine Carcinosarcoma, Small Cell Lung Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation, Colorectal Adenocarcinoma, Prostate Adenocarcinoma, Carcinoma of Unknown Primary, Other Histology
09/25
03/27
ONSEMBLE, NCT05593328: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Active, not recruiting
2
23
US
Onvansertib, FOLFIRI, Bevacizumab
Cardiff Oncology
Colorectal Cancer, Metastatic Colorectal Cancer
11/25
04/26
CaboMain, NCT05135975: A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Recruiting
2
86
US
Cabozantinib
Nationwide Children's Hospital, Exelixis
Neuroblastoma, Sarcoma
12/25
12/29
NCT05563272: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Recruiting
2
100
US
89Zr-DFO-girentuximab
Telix International Pty Ltd
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
12/25
12/25
ARTEMIS-002, NCT05830123: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting
2
170
RoW
HS-20093
Hansoh BioMedical R&D Company
Osteosarcoma, Sarcoma
12/25
12/27
NCT04278781: AG-120 in People With IDH1 Mutant Chondrosarcoma

Recruiting
2
17
US
AG-120
Memorial Sloan Kettering Cancer Center, Agios Pharmaceuticals, Inc.
Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
03/26
03/26
NCT04872543: A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Recruiting
2
25
US
ASTX727
Memorial Sloan Kettering Cancer Center, Astex Pharmaceuticals, Inc.
Malignant Peripheral Nerve Sheath Tumors (MPNST)
04/26
04/26
NCT05457829: Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Not yet recruiting
2
88
NA
Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine
Sun Yat-sen University, CSPC Ouyi Pharmaceutical Co., Ltd.
Rhabdomyosarcoma, Child
06/26
07/26
EMPIRE, NCT06084689: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
120
Europe
Ezabenlimab + BI907828
Institut Bergonié, Boehringer Ingelheim
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Biliary Tract Cancer
07/26
01/27
NCT05515575: A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Active, not recruiting
2
8
US
Niraparib
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Sarcoma,Soft Tissue, Sarcoma Uterus
08/26
08/26
NeoSarc, NCT06116578: Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Not yet recruiting
2
36
Europe
Pembrolizumab, WOO (Windows of opportunity), Pembrolizumab and Olaparib, Pembrolizumab adjuvant, Adjuvant
Gustave Roussy, Cancer Campus, Grand Paris, Merck Sharp & Dohme LLC
Cancer
09/26
06/28
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/26
10/26
NCT05879146: Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Not yet recruiting
2
40
US
Nirogacestat
M.D. Anderson Cancer Center, SpringWorks Therapeutics, Inc.
Tumor
01/27
01/28
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
02/27
09/28
MK-6482-015, NCT04924075 / 2020-005028-13: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations

Recruiting
2
322
Europe, Canada, Japan, US, RoW
Belzutifan, MK-6482, WELIREG™
Merck Sharp & Dohme LLC
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
02/27
02/27
ATA129-EBV-205, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
Swecranio, NCT05525273: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Recruiting
2
25
Europe
Oral dabrafenib and trametinib
Eva Marie Erfurth, MD, PhD, Novartis
Craniopharyngioma
09/27
04/28
NCT05949099: Study of Cryoablation and Nirogacestat for Desmoid Tumor

Recruiting
2
23
US
Nirogacestat, Cryoablation
Stanford University, SpringWorks Therapeutics, Inc.
Desmoid Tumor
02/28
02/28
NCT05879185: A Study of XmAb23104 in People With Sarcoma

Active, not recruiting
2
6
US
XmAb23104
Memorial Sloan Kettering Cancer Center, Xencor, Inc.
Sarcoma
04/25
04/25
NCT06087263: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Recruiting
2
30
US
Regorafenib, Stivarga®
M.D. Anderson Cancer Center, Bayer
Gastrointestinal Stromal Tumors
07/32
07/34
NCT04887298: Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Active, not recruiting
1b/2
36
US
Liposomal Annamycin (L-Annamycin)
Moleculin Biotech, Inc.
Sarcoma,Soft Tissue, Pulmonary Metastasis
05/24
05/24
2014-001549-26: Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients. Ensayo clínico que evalúa la combinación de Trabectedina y Radioterapia para el tratamiento de pacientes con sarcoma de tejidos blandas.

Ongoing
1/2
148
Europe
trabectedina, [trabectedina], Powder for concentrate for solution for infusion, YONDELIS 1 mg powder for concentrate for solution for infusion
GEIS, GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS, PharmaMar, Pharmamar
Soft Tissue Sarcoma Sarcoma de tejidos blandos, Soft Tissue Sarcoma Sarcoma de tejidos blandos, Diseases [C] - Cancer [C04]
 
 
2017-002243-15: An open-label study in patients with advanced cancer.

Not yet recruiting
1/2
63
Europe
IMCnyeso, IMCnyeso, Concentrate for solution for infusion
Immunocore Ltd., Immunocore Ltd.
HLA-A*0201 positive patients with advanced antigen-positive cancer with a histologic diagnosis of Non small cell lung carcinoma (NSCLC), melanoma, urothelial carcinoma, or synovial sarcoma with antigen positivity for NY-ESO-1 and/or LAGE-1A, Advanced NSCLC, melanoma, sarcoma and urothelial cancers., Diseases [C] - Cancer [C04]
 
 
NCT02453191: TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Completed
1/2
30
US
Talimogene Laherparepvec, Radiotherapy
University of Iowa, Amgen
Soft Tissue Sarcoma
01/19
03/23
2017-004761-28: A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs) Estudio de Selinexor en combinación con imatinib en pacientes con tumores gastrointestinales (GISTs) metastasicos o irresecables

Not yet recruiting
1/2
41
Europe
Selinexor, Glivec, KTP-330, STI571, Coated tablet, Tablet, Glivec
Grupo Español de Investigación en Sarcomas, Karyopharm
Gastrointestinal stromal tumor (GIST) Tumor del estroma gastrointestinal, Gastrointestinal stromal tumor (GIST) is a rare cancer affecting the digestive tract or nearby structures within the abdomen. Tumor del estroma gastrointestinal es un cancer raro que afecta el tracto digestivo y otras estructuras adyacentes en el abdomen, Diseases [C] - Cancer [C04]
 
 
2018-003120-36: An open-label study in patients with advanced cancer

Not yet recruiting
1/2
174
Europe
IMC-C103C, Atezolizumab, IMC-C103C, 1380723-44, Concentrate for solution for infusion, Tecentriq
Immunocore Limited, Immunocore Limited
Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma, Patients with advanced non-small cell lung cancer, head and neck cancer, esophageal cancer, gastric, bladder cancer (also called urothelial cancer), ovarian cancer and synovial sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT03250325: Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma

Hourglass Jan 2020 - Jan 2020 : P1/2 trial in unresectable progressive/recurrent synovial sarcoma
Completed
1/2
8
Japan
TBI-1301, Cyclophosphamide
Takara Bio Inc.
Synovial Sarcoma
01/20
03/22
NCT03676985: A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Osteosarcoma
02/20
06/23
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Completed
1/2
50
Europe
Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide
Institut Bergonié, PharmaMar
Soft-tissue Sarcomas
04/20
12/21
CS3007-101, NCT04254939: A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Checkmark Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Sep 2020 - Sep 2020: Preliminary results from a bridging study in Chinese Patients with Unresectable or Metastatic GIST
Checkmark Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
May 2020 - May 2020: Partial results from P1/2 bridging study in Chinese patients with unresectable or metastatic GIST at ASCO 2020
Completed
1/2
65
RoW
CS3007 (BLU-285)
CStone Pharmaceuticals, Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
04/20
04/23
2020-000505-80: A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer. Etude clinique de Phase I/IIa évaluant BT-001 chez des patients présentant des tumeurs solides avancées ou métastatiques.

Not yet recruiting
1/2
258
Europe
Pembrolizumab, BT-001, Solution for injection, Powder for concentrate for solution for infusion, Keytruda (pembrolizumab)
TRANSGENE, TRANSGENE, BioInvent International AB (publ)
Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase I: Tumeurs solides avancées ou métastatiques incluant les sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellulesPhase IIa: Sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellules, Advanced or metastatic solid tumors Tumeurs solides avancées ou métastatiques, Diseases [C] - Cancer [C04]
 
 
2021-001186-20: Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ensayo de diferentes esquemas de PM14 solo y en combinación con radioterapia en sarcomas de tejidos blandos y otros tumores sólidos.

Not yet recruiting
1/2
195
Europe
PM14, Lyophilisate for solution for infusion
GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS, GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS
Advanced soft tissue sarcoma and other solid tumors Sarcoma de tejidos blandos avanzado y otros tumores sólidos, Soft tissue tumors Tumores en tejidos blandos, Diseases [C] - Cancer [C04]
 
 
NCT03602833: Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

Active, not recruiting
1/2
12
Europe
Compound 451238
Royal Marsden NHS Foundation Trust, Merck KGaA, Darmstadt, Germany
Soft-tissue Sarcoma
05/22
01/23
2021-003762-13: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH PULMONARY METASTASES (ANNA-SARC)

Not yet recruiting
1/2
30
Europe
L-Annamycin, CP-507, Lyophilisate for solution for infusion
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB), Agencja Badan Medycznych, Moleculin Biotech
soft tissue sarcomas, soft tissue sarcomas, Diseases [C] - Cancer [C04]
 
 
NCT03345485: Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

Completed
1/2
71
Canada, US
Tinostamustine (EDO-S101)
Mundipharma Research Limited
Small-cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
2019-003034-16: Trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ensayo de LB-100 más doxorrubicina vs. doxorrubicina sola en primera lnea de sarcomas de tejidos blandos avanzados

Not yet recruiting
1/2
152
Europe
Doxorubicin, LB-100, Solution for infusion, Solution for injection, Doxorubicina Accord
Grupo Español de Investigación en Sarcomas (GEIS), Lixte Biotechnology Holdings, Inc.
Advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor) Sarcoma de tejidos blandos avanzado/metastásico (sarcoma pleomórfico indiferenciado, leiomiosarcoma, liposarcoma mixoide y liposarcoma hipercelular mixoide, mixofibrosarcoma, sarcomas no especificados en otra categoría, sarcoma sinovial, fibrosarcoma o tumor maligno de la vaina del nervio periférico), Advanced/metastatic soft tissue sarcoma Sarcoma de tejidos blandos avanzado/metastásico, Diseases [C] - Cancer [C04]
 
 
2021-005617-14: Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II) Estudio para evaluar la seguridad e identificar la dosis de ribociclib en combinación con temozolomida y topotecán (TOTEM) en pacientes (12 meses - 21 años) con tumores sólidos recidivantes o refractarios (Fase I) y evaluar la eficacia y seguridad en pacientes (12 meses - 21 años) con neuroblastoma recidivante o refractario (Fase II)

Ongoing
1/2
230
Europe, RoW
ribociclib, temozolomida 5 mg cápsulas duras, topotecan, temozolomida 20 mg cápsulas duras, temozolomida 100 mg cápsulas duras, temozolomida 140 mg cápsulas duras, temozolomida 180 mg cápsulas duras, temozolomida 250 mg cápsulas duras, LEE011, Powder for oral solution, Capsule, hard, Concentrate for solution for infusion, Temozolomid SUN & Temozolomid Accord, Potactasol & Hycamtin
Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG
relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old neuroblastoma recidivante o refractario y otros tumores sólidos (incluyendo meduloblastoma, glioma de alto grado, tumores rabdoides malignos y rabdomiosarcoma) en pacientes con edades comprendidas entre los 12 meses y los 21 años, Recurrent solid tumors in patients from 12 months to 21 years old Tumores sólidos recurrentes en pacientes con edades comprendidas entre los 12 meses y los 21 años, Diseases [C] - Cancer [C04]
 
 
NCT04260802: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Recruiting
1/2
116
Canada
OC-001, Drug: OC-001 in Combination with Avelumab
Ocellaris Pharma, Inc.
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer
03/26
09/26
NCT03422679 / 2017-001491-35: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Terminated
1/2
79
Europe, US, RoW
CB-103
Cellestia Biotech AG
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
11/22
11/22
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Active, not recruiting
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
02/25
2021-005086-41: Cell therapy clinical trial of BOXR1030 in GPC3 positive liver, squamous lung, Merkel cell cancer, and myxoid/round cell liposarcoma

Not yet recruiting
1/2
98
Europe
BOXR1030, Dispersion for infusion
SOTIO Biotech Inc, SOTIO Biotech a.s.
Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell liposarcoma, or Merkel cell carcinoma (MCC) with GPC3 overexpression by IHC, with a cytoplasmic/membranous H-score >30 for study eligibility. In the event of a tumor agnostic expansion cohort, other indications may be investigated., Patients with advanced, unresectable liver, squamous lung, and Merkel cell cancer, and myxoid/round cell liposarcoma that have tumor that is positive for GPC3 protein, Diseases [C] - Cancer [C04]
 
 
NCT03458728 / 2017-000383-15: Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Terminated
1/2
31
US
Copanlisib (BAY806946)
Bayer, Bayer AG
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
02/23
02/23
GEMMK, NCT03123276: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Active, not recruiting
1/2
24
Europe
Pembrolizumab, Keytruda, Gemcitabine
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Sarcoma
02/23
02/23
NCT04599062: TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active, not recruiting
1/2
8
US
Talimogene Laherparepvec, Radiotherapy
Mohammed Milhem, Amgen
Soft Tissue Sarcoma
02/23
11/24
KEYNOTE-A10, NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Checkmark Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Nov 2021 - Nov 2021: Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Completed
1/2
110
Canada, US
INT230-6, anti-PD-1 antibody, pembrolizumab, Keytruda, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016
Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
02/23
02/23
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Recruiting
1/2
73
RoW
CAR-T cell immunotherapy
Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University
B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma
03/23
03/23
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
2020-004246-11: This study will evaluate the safety, tolerability and efficacy of Tinostamustine in late-stage cancer patients. Different types of solid tumors will be treated with Tinostamustine. The study will be performed in multiple centers and countries.

Not yet recruiting
1/2
70
Europe
Tinostamustine, EDO-S101, Lyophilisate for solution for infusion
Mundipharma Research Limited, MUNDIPHARMA RESEARCH LIMITED, Mundipharma Research Limited
• Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refractory ovarian cancer • Cohort 5: Relapsed/refractory endometrial cancer On 05 March 2021 the Sponsor has taken the decision to halt recruitment into the Cohorts for relapsed/refractory triple-negative breast cancer (TNBC) and relapsed/refractory endometrial cancer on this study., "Relapse" means when a few of the original cancer cells survived the initial treatment. "Refractory" is a cancer that may be resistant at the beginning/becomes resistant during treatment., Diseases [C] - Cancer [C04]
 
 
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
NCT03338959: Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

Completed
1/2
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, NOS, Energy Type
Fred Hutchinson Cancer Center, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
06/23
08/23
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
NCT05602792: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Recruiting
1/2
233
RoW
T3011
ImmVira Pharma Co. Ltd
Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer
07/23
01/24
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
TQB2858-I-05, NCT05154630: Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Terminated
1/2
8
RoW
TQB2858 injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer, Advanced Soft-tissue Sarcoma
03/23
06/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
PM1183-A-014-15, NCT02611024: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Recruiting
1/2
320
Europe, US
Lurbinectedin, PM01183, Irinotecan
PharmaMar
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
03/26
03/26
ALMB-0168-CN-101, NCT04886765: A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Not yet recruiting
1/2
238
NA
ALMB-0168
AlaMab Therapeutics (Shanghai) Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Osteosarcoma
11/23
05/24
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Active, not recruiting
1/2
15
US
YH001, Envafolimab, KN035, Doxorubicin
Tracon Pharmaceuticals Inc.
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
11/23
09/25
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
224
US, RoW
APG-115+Pembrolizumab, Keytruda
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, MPNST, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors
12/24
03/25
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma

Recruiting
1/2
45
US
Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
12/24
03/25
NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting
1/2
56
US
AL3818, Anlotinib hydrochloride, Nivolumab Injection, Opdivo
Sarcoma Oncology Research Center, LLC, Advenchen Laboratories, LLC
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
12/24
03/25
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT04220229: Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Active, not recruiting
1/2
6
US
Cabozantinib S-malate, 1140909-48-3, BMS-907351, Butanedioic acid, Cabometyx, Cometriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
University of Washington, Exelixis
Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
04/24
01/27
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
12/24
12/25
NCT04742959: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed
1/2
203
US
TT-00420, Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
02/24
02/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
05/24
09/24
NCT05160168: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Terminated
1/2
32
US
THE-630
Theseus Pharmaceuticals
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
02/24
02/24
NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Recruiting
1/2
36
US
Mebendazole, Vermox, Vincristine, Oncovin, Carboplatin, Paraplatin, Temozolomide, Temodar, Bevacizumab, Avastin, Irinotecan, CPT-11, Camptosar
Julie Krystal, Janssen Pharmaceuticals
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
04/24
04/25
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Recruiting
1/2
95
RoW
APG-115, Toripalimab
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Liposarcoma, Advanced Solid Tumor
04/26
01/27
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NCT06384248: Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Not yet recruiting
1/2
30
NA
LTC004
Letolab
Unresectable or Metastatic Sarcoma
12/25
12/25
NCT04579757: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
135
US
Surufatinib and Tislelizumab _ Part 1, HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 2
Hutchmed, BeiGene
Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
04/24
06/24
NCT05166577: Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Recruiting
1/2
130
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
12/24
10/25
INJECTABL-1, NCT05688280: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Recruiting
1/2
44
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
05/24
05/24
PHANTOM, NCT06298916: 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Not yet recruiting
1/2
32
NA
64Cu-LNTH-1363S
Lantheus Medical Imaging
Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
11/25
04/26
NCT06380816: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Not yet recruiting
1/2
167
Europe
UCB4594
Cancer Research UK, UCB Biopharma SRL
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms, Carcinoma, Renal Cell (Clear Cell Only), Esophageal Neoplasms, Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors), Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
11/29
11/29
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Active, not recruiting
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
09/24
LIGHTBEAM-U01, NCT06395103: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/)

Recruiting
1/2
90
RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
03/29
03/29
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/24
06/24
KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting
1/2
314
US
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Kineta Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
06/24
12/24
NCT05099666: Lurbinectedin + Doxorubicin In Leiomyosarcoma

Recruiting
1/2
62
US
Lurbinectedin, Zepzelca, Doxorubicin, Adriamycin
Massachusetts General Hospital, Jazz Pharmaceuticals
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
07/24
07/25
DUET-1, NCT05120271: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Recruiting
1/2
110
US
CAR-GPC3 T Cells, BOXR1030
Sotio Biotech Inc., SOTIO Biotech AG, SOTIO Biotech a.s.
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
04/26
12/41
NCT06217536: Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas

Not yet recruiting
1/2
70
US
Lurbinectedin, Zepzelca, Radiotherapy, Radiation therapy, Non-investigational surgery
University of California, San Francisco, Jazz Pharmaceuticals
Locally Advanced Soft Tissue Sarcoma
01/26
07/27
NCT06465199: Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Not yet recruiting
1/2
253
NA
Difluoromethylornithine (DFMO), Eflornithine, AMXT-1501 Dicaprate
Milton S. Hershey Medical Center, Aminex Therapeutics, Inc.
Atypical Teratoid/Rhabdoid Tumor, Neuroblastoma Recurrent, Embryonal Tumor With Multilayered Rosettes, DIPG Brain Tumor, Ewing Sarcoma, Osteosarcoma Recurrent
07/32
07/34
NCT03709680 / 2021-003444-25: Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting
1/2
128
Europe, Canada, US, RoW
Palbociclib, Ibrance, Temozolomide, Temodar, Irinotecan, Campto, Topotecan, Hycamtin, Cyclophosphamide, Cytoxan
Pfizer, Children's Oncology Group (COG)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
08/24
02/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Recruiting
1/2
38
RoW
Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor
Sun Yat-sen University, Hutchmed
Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer
08/24
08/25
 

Download Options